source
- Compass Pathways reports positive one-year data for its psilocybin therapy COMP360Compass Pathways released results from a one-year study of its psilocybin‑based therapy COMP360. The company described the data as positive, indicating continued promise for the investigational tre…
- FDA appoints permanent heads of CDER and CBER, adding AI deputy roleThe Trump administration announced permanent appointments to two key FDA centers after a period of turnover. Michael Davis, who had been acting director of the Center for Drug Evaluation and Resea…